TB-500 vs. BPC-157: What the Research Actually Compares

The story below is a composite of real experiences; details changed.

Eight weeks after the strain, Ryan Cole still climbs the ladder one careful rung at a time. The pull high in the back of his thigh hasn’t let go.

He’s 37 and a roofer. A hamstring that won’t settle means slow days on the roof and a crew picking up his slack.

His crew lead swears by “the combo.” A guy at his gym says one of the two is overrated. A podcast host says you need both.

Everyone has an opinion on BPC-157 versus TB-500. When Ryan tries to line up what’s actually been studied, he sees the problem: most comparisons online compare claims, not studies.

So let’s compare the studies: what each one is, what’s been tested in people, and five checks for any comparison you read.

Two different molecules

BPC-157 is a lab-made peptide, a chain of 15 amino acids. TB-500 is a lab-made chain of 7 amino acids. It copies one small section of thymosin beta-4, a natural protein with 43 amino acids, and adds a chemical cap on one end. (FDA TB-500 briefing; FDA BPC-157 briefing)

That last detail matters more than it sounds. Research on thymosin beta-4 is not research on TB-500. A 7-piece fragment may not behave like the 43-piece protein it came from.

In one lab test the FDA reviewed, TB-500 did not promote wound healing in cell cultures at the concentration tested. A related breakdown product did show activity. (FDA)

Plain-English profiles of each, from the team behind After the Scope: BPC-157, TB-500 and the two together, in the Peptides Made Simple peptide library.

Side by side

Sources: FDA BPC-157 briefing; FDA TB-500 briefing; ClinicalTrials.gov; USADA.

The honest summary: one has thin human data, and the other has essentially none. Neither has published results showing faster injury recovery in people.

What about thymosin beta-4?

The full protein has been tested in people. Small phase 2 trials used it as eye drops for dry eye and as a gel on slow-healing skin wounds. (dry-eye trial; skin-wound trial record)

Those studies are real. But they tested a different molecule, applied to eyes and skin. They don’t tell you what an injected 7-amino-acid fragment does to a hamstring or a rotator cuff.

What the FDA and its advisers said

In July 2026 both peptides came up for a vote on whether pharmacies may compound them. FDA staff recommended against both. For TB-500 they wrote that they found no articles in which it was given to people.

They also flagged risk of immune reactions and missing tests for impurities, clumping and bacterial toxins. (FDA)

The FDA’s outside advisory panel voted the other way. That vote is a recommendation only. Pharmacies can’t compound either one until the FDA issues a final rule, and as of mid-September 2026 it hadn’t. (Frier Levitt)

A panel vote isn’t an approval. Neither peptide is an FDA-approved drug. For the full BPC-157 picture, read what the BPC-157 research actually shows.

Five checks for any peptide comparison

If a post fails the first three, it’s opinion. For a quick way to size up the stories behind it, read how to evaluate a recovery claim.

For why identity and impurity testing matter, read what’s in the other 1%.

The spreadsheet he didn’t need

Ryan’s comparison ends up as two short columns. One says “thin.” The other says “none found.”

Eight weeks of careful rungs would make anyone want a shortcut. Wanting one isn’t weakness. It just isn’t evidence.

He books a physical therapy evaluation for the hamstring and saves his questions for that visit.

The best comparison isn’t this peptide versus that one. It’s evidence versus marketing.

Your next step: run the next peptide comparison you read through the five checks. If it fails the first three, close the tab.

---

Ryan is a composite, drawn from the kinds of questions people ask during recovery. The details are illustrative. This article is education, not medical advice. It does not cover dosing or use.